Compass Pathways (NASDAQ:CMPS) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen downgraded shares of Compass Pathways (NASDAQ:CMPS) from a hold rating to a strong sell rating in a research report sent to investors on Saturday.

A number of other analysts have also recently issued reports on the company. Evercore upgraded Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price objective on the stock in a research report on Wednesday, July 8th. Canaccord Genuity Group raised their target price on Compass Pathways from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, June 26th. Stifel Nicolaus lifted their price target on shares of Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Oppenheimer reissued an “outperform” rating on shares of Compass Pathways in a report on Wednesday. Finally, UBS Group set a $18.00 price objective on shares of Compass Pathways in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Compass Pathways has a consensus rating of “Moderate Buy” and a consensus target price of $23.36.

Compass Pathways Stock Down 0.1%

CMPS stock opened at $13.54 on Friday. Compass Pathways has a twelve month low of $3.97 and a twelve month high of $15.40. The company has a quick ratio of 3.32, a current ratio of 1.30 and a debt-to-equity ratio of 0.60. The company has a market cap of $1.83 billion, a PE ratio of -2.93 and a beta of 2.50. The business’s 50-day simple moving average is $12.59 and its 200 day simple moving average is $9.34.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) EPS for the quarter, missing the consensus estimate of ($0.39) by ($1.49). On average, research analysts anticipate that Compass Pathways will post -1.25 earnings per share for the current year.

Hedge Funds Weigh In On Compass Pathways

Hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its stake in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after buying an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd acquired a new position in Compass Pathways during the fourth quarter worth $38,000. Caitong International Asset Management Co. Ltd acquired a new position in Compass Pathways during the fourth quarter worth $47,000. Advisory Services Network LLC bought a new position in shares of Compass Pathways during the third quarter valued at $41,000. Finally, Parallel Advisors LLC lifted its holdings in shares of Compass Pathways by 8,450.6% during the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after acquiring an additional 7,183 shares during the period. 46.19% of the stock is owned by institutional investors and hedge funds.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.